SEARCH

SEARCH BY CITATION

References

  • 1
    Ardizzone S. Ulcerative Colitis. Orphanet Encylcopedia 2003. Available at: http://www.orpha.net/data/patho/GB/uk-UC.pdf. Last accessed November 2005.
  • 2
    Schmidt C, Stallmach A. Etiology and pathogenesis of inflammatory bowel disease. Minerva Gastroenterol Dietol 2005; 51: 12745.
  • 3
    Kovvali G, Das KM. Molecular mimicry may contribute to pathogenesis of ulcerative colitis. FEBS Lett 2005; 579: 22616.
  • 4
    Wen Z, Fiocchi C. Inflammatory bowel disease: autoimmune or immune-mediated pathogenesis? Clin Dev Immunol 2004; 11: 195204.
  • 5
    Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2003; CD000543.
  • 6
    Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2002; CD000544.
  • 7
    Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004; 27: 121824.
  • 8
    Murphy DA, Sarr M, Durako SJ, Moscicki A-B, Wilson CM, Muenz LR. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med 2003; 157: 24955.
  • 9
    Loghman-Adham M. Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care 2003; 9: 15571.
  • 10
    Peura D. Helicobacter pylori: rational management options. Am J Med 1998; 105: 42430.
  • 11
    DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002; 40: 794811.
  • 12
    World HO. Adherence to Long-term Therapies. Evidence for Action2003. Available at: http://www.who.int/chronicconditions/adherencereport/en/, accessed July 2005.
  • 13
    Rudd P. Clinicians and patients with hypertension: unsettled issues about compliance. Am Heart J 1995; 130: 5729.
  • 14
    Morris AD, Brennan GM, MacDonald TM, Donnan PT. Population-based adherence to prescribed medication in type 2 diabetes: a cause for concern. Diabetes 2000; 49 (Suppl 1): A76.
  • 15
    Farup P, Hinterleitner T, Lukas M, et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis 2001; 7: 23742.
  • 16
    Hanauer SB, Sninsky CA, Robinson M, et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial. Ann Intern Med 1996; 124: 20411.
  • 17
    Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005; 11: 4217.
  • 18
    Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 292933.
    Direct Link:
  • 19
    Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 3943.
  • 20
    Levy RL, Feld AD. Increasing patient adherence to gastroenterology treatment and prevention regimens. Am J Gastroenterol 1999; 94: 173342.
    Direct Link:
  • 21
    Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 1918.
  • 22
    van Hees PA, van Tongeren JH. Compliance to therapy in patients on a maintenance dose of sulfasalazine. J Clin Gastroenterol 1982; 4: 3336.
  • 23
    Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003; 98: 153544.
    Direct Link:
  • 24
    Gionchetti P, Ardizzone S, Benvenuti ME, et al. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. Aliment Pharmacol Ther 1999; 13: 3818.
  • 25
    Kane SV, Hanauer SB. National adherence rates with IBD therapy: PO vs PR. Am J Gastroenterol 2001; 96: S296.
  • 26
    Bresci G, Parisi G, Bertoni M, Capria A. Long-term maintenance treatment in ulcerative colitis: a 10-year follow-up. Dig Liver Dis 2002; 34: 41923.
  • 27
    Han SW, McColl E, Barton JR, et al. Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations. Inflamm Bowel Dis 2005; 11: 2434.
  • 28
    Janke KH, Klump B, Gregor M, Meisner C, Haeuser W. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 27286.
  • 29
    Saibeni S, Cortinovis I, Beretta L, et al. Gender and disease activity influence health-related quality of life in inflammatory bowel diseases. Hepatogastroenterology 2005; 52: 50915.
  • 30
    Janke KH, Raible A, Bauer M, et al. Questions on life satisfaction (FLZM) in inflammatory bowel disease. Int J Colorectal Dis 2004; 19: 34353.
  • 31
    Brentnall TA. Molecular underpinnings of cancer in ulcerative colitis. Curr Opin Gastroenterol 2003; 19: 648.
  • 32
    Moody GA, Jayanthi V, Probert CS, Mac Kay H, Mayberry JF. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8: 117983.
  • 33
    Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case–control study. Aliment Pharmacol Ther 2000; 14: 14553.
  • 34
    Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO. Risk factors for colorectal cancer in patients with ulcerative colitis: a case–control study. Gastroenterology 1994; 107: 11720.
  • 35
    van Staa TP, Card TR, Leufkens HG, Logan RF. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005; 54: 15738.
  • 36
    Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100: 134553.
    Direct Link:
  • 37
    Aliotta SL, Vlasnik JJ, Delor B. Enhancing adherence to long-term medical therapy: a new approach to assessing and treating patients. Adv Ther 2004; 21: 21431.
  • 38
    Dezii CM. Medication noncompliance: what is the problem? Manag Care 2000; 9 (Suppl.) 712.
  • 39
    Bernstein CN, Papineau N, Zajaczkowski J, et al. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol 2000; 95: 67783.
    Direct Link:
  • 40
    Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol 1997; 32: 11349.
  • 41
    Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol 1992; 14: 30917.
  • 42
    Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53: 14718.
  • 43
    Cleemput I, Kesteloot K. Economic implications of non-compliance in health care. Lancet 2002; 359: 212930.
  • 44
    Bernstein CN, Kraut A, Blanchard JF, et al. The relationship between inflammatory bowel disease and socioeconomic variables. Am J Gastroenterol 2001; 96: 211725.
    Direct Link:
  • 45
    Longobardi T, Jacobs P, Wu L, Bernstein CN. Work losses related to inflammatory bowel disease in Canada: results from a National Population Health Survey. Am J Gastroenterol 2003; 98: 8449.
    Direct Link:
  • 46
    Marri SR, Buchman AL. The education and employment status of patients with inflammatory bowel diseases. Inflamm Bowel Dis 2005; 11: 1717.
  • 47
    Piodi LP, Ulivieri FM, Cermesoni L, Cesana BM. Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis. Scand J Gastroenterol 2004; 39: 1547.
  • 48
    Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996; 348: 3836.
  • 49
    Domino FJ. Improving adherence to treatment for hypertension. Am Fam Physician 2005; 71: 208990.
  • 50
    Hawkins T. Impact of once- and twice-daily dosing regimens on adherence and overall safety. AIDS Read 2004; 14: 346.
  • 51
    Kardas P. Comparison of once daily versus twice daily oral nitrates in stable angina pectoris. Am J Cardiol 2004; 94: 2136.
  • 52
    Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005; 80: 85661.
  • 53
    Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003; 1: 1703.
  • 54
    Lichtenstein G, Kamm MA, Sandborn WJ, et al.SPD476 is a novel, once-daily, high-dose, effective and well tolerated 5ASA formulation for the induction of remission of mild-to-moderate ulcerative colitis: a phase III study. ACG 2005; 100 (Suppl.): A21.
  • 55
    Kamm M, Sandborn WJ, Gassull M, et al. Comparison of the efficacy and safety of SPD476, a novel, once-daily, high dose formulation of mesalamine, and Asacol with placebo for the induction of remission of mild-moderate ulcerative colitis: a phase III study. ACG 2005; 100 (Suppl.): A22.
  • 56
    Brunner M, Greinwald R, Kletter K, et al. Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Aliment Pharmacol Ther 2003; 17: 11639.
  • 57
    Wilding I, Behrens C, Tardif S, et al. Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects. Aliment Pharmacol Ther 2003; 17: 115362.
  • 58
    Lamet M, Ptak T, Dallaire C, et al. Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. Inflamm Bowel Dis 2005; 11: 62530.
  • 59
    Aumais G, Lefebvre M, Massicotte J, et al. Pharmacokinetics and pilot efficacy of a mesalazine rectal gel in distal ulcerative colitis. Drugs R D 2005; 6: 416.